2 August 2026
Executive Summary
India’s medicines regulator has taken enforcement action against approximately 90% of pharmaceutical manufacturing facilities identified as high-risk during a nationwide inspection programme.
More than 960 risk-based inspections were undertaken, with action reportedly taken against around 860 facilities. Measures included production stoppages, licence suspensions and licence cancellations.
The programme follows international concern over the quality of certain Indian-manufactured medicines and forms part of a broader effort to improve compliance with recognised manufacturing standards.
India is one of the world’s most important producers of generic medicines and pharmaceutical ingredients, meaning that regulatory action affecting its manufacturing base may have consequences far beyond the domestic market.
UK Impact
UK healthcare providers, distributors, pharmacies and pharmaceutical companies may depend directly or indirectly upon Indian manufacturers.
Potential effects include:
- Temporary shortages where production is halted.
- Delays while buyers qualify alternative suppliers.
- Increased quality-testing and documentary requirements.
- Product recalls or enhanced batch scrutiny.
- Higher procurement and logistics costs.
- Contract disputes concerning rejected or delayed goods.
Businesses may also need to confirm whether the inspected facility is the actual manufacturer, rather than relying solely upon the name of an importer, distributor or brand owner.
Global Impact
India supplies medicines and active pharmaceutical ingredients to markets worldwide.
Stronger enforcement may improve confidence in the industry over the longer term, but the transition could create short-term disruption where non-compliant facilities lose capacity.
International buyers may increasingly demand:
- Detailed manufacturing-site information.
- Evidence of regulatory inspections.
- Batch-level traceability.
- Good Manufacturing Practice certification.
- Stronger quality warranties and indemnities.
- Immediate notification of regulatory action.
The regulator is also increasing its use of digital systems and exploring artificial intelligence to support inspections, reporting and safety evaluation.
Our View
Lowest-cost sourcing is not commercially attractive where the buyer cannot verify the facility producing the medicine or ingredient.
Businesses should:
- Identify the exact manufacturing site for each critical product.
- Confirm its inspection and enforcement history.
- Review product-quality and recall provisions within contracts.
- Establish alternative suppliers for essential medicines and ingredients.
- Require prompt disclosure of licence suspensions or production stoppages.
- Assess whether insurance responds to contamination, recall and consequential losses.
The crackdown should ultimately strengthen the market, but businesses should prepare for disruption while weaker facilities are removed or required to improve.
Risk Indicator: ELEVATED
Disclaimer
The information contained within these Market Alerts is provided for general market awareness and informational purposes only. It does not constitute financial, legal, investment, regulatory or insurance advice. Whilst every effort has been made to ensure accuracy at the time of publication using multiple reputable and independently verified sources, geopolitical events, legislation, regulation and market conditions may change rapidly. Readers should obtain appropriate professional advice before acting upon any information contained herein.
Invictus Risk Solutions LLP – Helping organisations stay ahead of emerging risks through informed insight and independent analysis.